Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Aptose Biosciences Inc. has successfully closed a registered direct offering of 3,855,000 common shares at a price of $1.15 per share, raising approximately $4.43 million in gross proceeds, which will be used for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering included both registered common shares and unregistered series A and B warrants, each exercisable at $1.15 per share [1]. - The series A warrants will expire five years from shareholder approval, while the series B warrants will expire eighteen months from the same approval [1]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5]. - The company's pipeline includes two clinical-stage oral kinase inhibitors: tuspetinib, which is being developed for acute myeloid leukemia (AML), and luxeptinib, aimed at treating relapsed or refractory hematologic malignancies [5].